Late-stage insoluble protein aggregates may have very little relevance to the pathogenic mechanisms of disease, and therefore targeting pre-fibrillar tau and/or Aβ species will be a more effective therapeutic strategy for AD. Here, MAPT is linked to Alzheimer disease.